LIGAND PHARMACEUTICALS INCORPORATED
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $60.7M | $58.9M | $1.9M | $18.9M |
| FY2017 | $88.6M | $86.4M | $2.2M | $24.9M |
| FY2018 | $194.1M | $193.2M | $887.0K | $20.8M |
| FY2019 | $-29.3M | $-31.9M | $2.6M | $24.5M |
| FY2020 | $54.6M | $50.1M | $4.5M | $30.7M |
| FY2021 | $78.8M | $70.0M | $8.8M | $38.8M |
| FY2022 | $137.9M | $119.9M | $17.9M | $60.3M |
| FY2023 | $49.6M | $46.1M | $3.5M | $25.7M |
| FY2024 | $97.0M | $95.2M | $1.8M | $41.1M |
| FY2025 | $49.4M | $48.9M | $452.0K | $46.8M |